Guidelines for the treatment of rapidly progressive glomerulonephritis, second version

Japanese Journal of Nephrology

Volumn 53, Issue 4, 2011, Pages 509-555

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

PRACTICE GUIDELINE; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW;

CAUSE OF DEATH; DISEASE PROGRESSION; GLOMERULONEPHRITIS; HUMANS; PROGNOSIS; REFERENCE STANDARDS; SEVERITY OF ILLNESS INDEX;

EID: 79959487728     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Koyama A, Yamagata K, Makino H, Arimura Y, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan '? etiology, prognosis and treatment diversity. Clin Exp Nephrol 2009 ; 13 : 633-650.
2. Lapraik C, Watts R, Bacon P, Carruthers D, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 ; 46 : 1615-1616.
3. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009 ; 68 : 310-317.
4. Churg J, Bernstein J, Glassock RJ. Classification of glomerular disease. In : Churg J, Bernstein J, Glassock RJ (eds) Renal disease. Classification and atlas of glomerular diseases. 2nd ed. New York, Tokyo : Igaku-Shoin, 1995 : 11.
5. Jannette JC. Crescentic glomerulonephritis. In : Jannette JC, Olson JL, Schwartz MM, Silva FG(eds). Heptinstall's pathology of the kidney 5th ed, Philadelphia, New York:Lippincott-Raven, 1998 : 625-656.
6. Lionaki S, Jennette JC, Falk RJ. Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis. Semin Immunopathol 2007 ; 29 : 459-474. (Pubitemid 350077264)
7. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody : possible arbovirus aetiology? Br Med J (Clin Res Ed) 1982 ; 285 : 606.
8. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988 ; 318 : 1651-1657.
9. Nassberger L, Sjoholm AG, Bygren P, Thysell H, et al. Circulating anti-neutrophil cytoplasm antibodies in patients with rapidly progressive glomerulonephritis and extracapillary proliferation. J Intern Med 1989 ; 225 : 191-196. (Pubitemid 19118440)
10. Franssen CF, Stegeman CA, Kallenberg CG, Gans RO, et al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int 2000 ; 57 : 2195-2206.
11. Fujimoto S, Uezono S, Hisanaga S, Fukudome K, et al. Incidence of ANCA-associated primary renal vasculitis in the Miyazaki prefecture : the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol 2006 ; 1 : 1016-1022.
12. Tsuchiya N, Kobayashi S, Kawasaki A, Kyogoku C, et al. Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis : association of HLA-DRBl*0901 with microscopic polyangiitis. J Rheumatol 2003 ; 30 : 1534-1540. (Pubitemid 36835452)
13. Tsuchiya N, Kobayashi S, Hashimoto H, Ozaki S, et al. Association of HLA-DRB1*0901-DQB1*0303 haplotype with microscopic polyangiitis in Japanese. Genes Immun 2006 ; 7 : 81-84.
14. Yashiro M, Muso E, Itoh-Ihara T, Oyama A, et al. Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). Am J Kidney Dis 2000 ; 35 : 889-895. (Pubitemid 30238202)
15. Ito-Ihara T, Muso E, Kobayashi S, Uno K, et al. A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe. Clin Exp Rheumatol 2008 ; 26 : 1027-1033.
16. Yamagata K, Hirayama K, Mase K, Yamaguchi N, et al. Apheresis for MPO-ANCA-associated RPGN-indications and efficacy : lessons learned from Japan nationwide survey of RPGN. J Clin Apher 2005 ; 20 : 244-251.
17. Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996 ; 39 : 9-22.
18. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990 ; 87 : 4115-4119. (Pubitemid 20217992)
19. Rarok AA, Limburg PC, Kallenberg CG. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol 2003 ; 74 : 3-15. (Pubitemid 38040431)
20. Hess C, Sadallah S, Schifferli JA. Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. Blood 2000 ; 96 : 2822-2827.
21. Nagao T, Matsumura M, Mabuchi A, Ishida-Okawara A, et al. Up-regulation of adhesion molecule expression in glomerular endothelial cells by anti-myeloperoxidase antibody. Nephrol Dial Transplant 2007 ; 22 : 77-87.
22. Brinkmann V, Reichard U, Goosmann C, Fauler B, et al. Neutrophil extracellular traps kill bacteria. Science 2004 ; 303 : 1532-1535. (Pubitemid 38314426)
23. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009 ; 15 : 623-625.
24. Bernis P, Hamels J, Quoidbach A, Mahieu P, et al. Remission of Goodpasture's syndrome after withdrawal of an unusual toxic. Clin Nephrol 1985 ; 23 : 312-317. (Pubitemid 15059844)
25. Saus J, Wieslander J, Langeveld JP, Quinones S, et al. Identification of the Goodpasture antigen as the alpha 3 (IV) chain of collagen IV. J Biol Chem 1988 ; 263 : 13374-13380.
26. Kalluri R, Wilson CB, Weber M, Gunwar S, et al. Identification of the alpha 3 chain of typeIV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. J Am Soc Nephrol 1995 ; 6 : 1178-1185.
27. Pedchenko V, Bondar O, Fogo AB, Vanacore R, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 363 : 343-354.
28. Esnault VL, Soleimani B, Keogan MT, Brownlee AA, et al. Association of IgM with IgG ANCA in patients presenting with pulmonary hemorrhage. Kidney Int 1992 ; 41 : 1304-1310.
29. Muller Kobold AC, van der Geld YM, Limburg PC, Tervaert JW, et al. Pathophysiology of ANCA-associated glomerulonephritis. Nephrol Dial Transplant 1999 ; 14 : 1366-1375.
30. Hellmich B, Flossmann O, Gross WL, Bacon P, et al. EULAR recommendations for conducting clinical studies and/ or clinical trials in systemic vasculitis : focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007 ;66 : 605-617. (Pubitemid 46707128)
31. Kussmaul A, Maier R. Uber eine nicht bisher beschriebene eigenthumliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskelahmung einhergeht. Deutsche Archiv Klinische Medizin 1866 ; 1 : 484-518.
32. Watts R, Lane S, Hanslik T, Hauser T, et al. Development and validation of a consensus methodology for the classifica- tion of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007 ; 66 : 222-227. (Pubitemid 46226058)
33. Wiik A. Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxford) 2002 ; 41 : 481-483. (Pubitemid 34567175)
34. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis : a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008 ; 67 : 1004-1010. (Pubitemid 351956664)
35. Pankhurst T, Savage CO, Gordon C, Harper L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford) 2004 ; 43 : 1532-1535.
36. Annual Review 2007. 2007 : 69-75.
37. Hedger N, Stevens J, Drey N, Walker S, et al. Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK : a 10-year retrospective study. Nephrol Dial Transplant 2000 ; 15 : 1593-1599.
38. Chen M, Yu F, Wang SX, Zou WZ, et al. Antineutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis. J Am Soc Nephrol 2007 ; 18 : 599-605. (Pubitemid 46193325)
39. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, et al. Renal histology in ANCA-associated vasculitis : differences between diagnostic and serologic subgroups. Kidney Int 2002 ; 61 : 80-89.
40. Levy JB, Pusey CD. Crescentic glomerulonephritis. In : Brady HR, Wilcox CS (eds). Therapy in nephrology and hypertension. 2nd ed. London : Saunders, 2003 : 177-188.
41. Little MA, Pusey CD. Rapidly progressive glomerulonephritis : current and evolving treatment strategies. J Nephrol 2004 ; 17(Suppl 8) : S10-19.
42. Benoit FL, Rulon DB, Theil GB, Doolan PD, et al. Goodpasture's syndrome : a clinicopathologic entity. Am J Med 1964 ; 37 : 424-444.
43. Proskey AJ, Weatherbee L, Easterling RE, Greene JA Jr, et al. Goodpasture's syndrome. A report of five cases and review of the literature. Am J Med 1970 ; 48 : 162-173.
44. Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973 ; 3 : 74-89.
45. Beirne GJ, Wagnild JP, Zimmerman SW, Macken PD, et al. Idiopathic crescentic glomerulonephritis. Medicine (Baltimore) 1977 ; 56 : 349-381. (Pubitemid 8195309)
46. Teague CA, Doak PB, Simpson IJ, Rainer SP, et al. Goodpasture's syndrome : an analysis of 29 cases. Kidney Int 1978 ; 13 : 492-504.
47. Briggs WA, Johnson JP, Teichman S, Yeager HC, et al. Anti-glomerular basement membrane antibody-mediated glomerulonephritis and Goodpasture's syndrome. Medicine (Baltimore) 1979 ; 58 : 348-361. (Pubitemid 10234878)
48. Peters DK, Rees AJ, Lockwood CM, Pusey CD. Treatment and prognosis in antibasement membrane antibody-mediated nephritis. Transplant Proc 1982 ; 14 : 513-521. (Pubitemid 13197323)
49. Simpson IJ, Doak PB, Williams LC, Blacklock HA, et al. Plasma exchange in Goodpasture's syndrome. Am J Nephrol 1982 ; 2 : 301-311. (Pubitemid 13181772)
50. Walker RG, Scheinkestel C, Becker GJ, Owen JE, et al. Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM) nephritis/Goodpasture's syndrome. Q J Med 1985 ; 54 : 75-89.
51. Johnson JP, Moore J, Jr., Austin HA, 3rd, Balow JE, et al. Therapy of anti-glomerular basement membrane antibody disease : analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985 ; 64 : 219-227. (Pubitemid 16247105)
52. Savage CO, Pusey CD, Bowman C, Rees AJ, et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986 ; 292 : 301-304.
53. Herody M, Bobrie G, Gouarin C, Grunfeld JP, et al. Anti-GBM disease : predictive value of clinical, histological and serological data. Clin Nephrol 1993 ; 40 : 249-255.
54. Merkel F, Pullig O, Marx M, Netzer KO, et al. Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease : report of 35 cases. Nephrol Dial Transplant 1994 ; 9 : 372-376. (Pubitemid 24136268)
55. Daly C, Conlon PJ, Medwar W, Walshe JJ. Characteristics and outcome of anti-glomerular basement membrane disease : a single-center experience. Ren Fail 1996 ; 18 : 105-112. (Pubitemid 26073879)
56. Li FK, Tse KC, Lam MF, Yip TP, et al. Incidence and outcome of antiglomerular basement membrane disease in Chinese. Nephrology (Carlton) 2004 ; 9 : 100-104. (Pubitemid 38530453)
57. Cui Z, Zhao MH, Xin G, Wang HY. Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron Clin Pract 2005 ; 99 : c49-55.
58. Turner AN, Rees AJ. Anti-glomerular basement membrane antibody disease. In : Brandy HR, Wilcox CS (eds). Therapy in nephrology and hypertension : a companion to Brenner and Rector's The Kidney. Philadelphia, Toronto, Montreal, Sydney, Tokyo : WB Saunders, 1998 : 152-157.
59. Flores JC, Taube D, Savage CO, Cameron JS, et al. Clinical and immunological evolution of oligoanuric anti-GBM nephritis treated by haemodialysis. Lancet 1986 ; 1 : 5-8. (Pubitemid 16182816)
60. Naicker S, Fabian J, Naidoo S, Wadee S, et al. Infection and glomerulonephritis. Semin Immunopathol 2007 ; 29 : 397-414.
61. Zent R, Van Zyl Smit R, Duffield M, Cassidy MJ. Crescentic nephritis at Groote Schuur Hospital, South Africa - not a benign disease. Clin Nephrol 1994 ; 42 : 22-29.
62. Daimon S, Mizuno Y, Fujii S, Mukai K, et al. Infective endocarditis-induced crescentic glomerulonephritis dramatically improved by plasmapheresis. Am J Kidney Dis 1998 ; 32 : 309-313.
63. Iwata Y, Ohta S, Kawai K, Yamahana J, et al. Shunt nephritis with positive titers for ANCA specific for proteinase 3. Am J Kidney Dis 2004 ; 43 : e11-16.
64. Koyama A, Kobayashi M, Yamaguchi N, Yamagata K, et al. Glomerulonephritis associated with MRSA infection : a possible role of bacterial superantigen. Kidney Int 1995 : 47 : 207-216.
65. Hirayama K, Kobayashi M, Hashimoto Y, Usui J, et al. Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. Am J Kidney Dis 2004 ; 44 : 57-63. (Pubitemid 38880927)
66. Turnbull J, Harper L. Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 2009 ; 23 : 391-401.
67. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007 : CD005590.
68. Gluck T. Vaccinate your immunocompromised patients! Rheumatology (Oxford) 2006 ; 45 : 9-10.
69. Hader JE, Marzella L, Myers RA, Jacobs SC, et al. Hyperbaric oxygen treatment for experimental cyclophosphamide-induced hemorrhagic cystitis. J Urol 1993 ; 149 : 1617-1621. (Pubitemid 23164585)
70. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases : a data-driven review. Arthritis Rheum 2010 ; 62 : 9-21.
71. Hows JM, Mehta A, Ward L, Woods K, et al. Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation : a prospective randomised study. Br J Cancer 1984 ; 50 : 753-756.
72. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, et al. Wegener granulomatosis : an analysis of 158 patients. Ann Intern Med 1992 ; 116 : 488-498.
73. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002 ; 100 : 82-85. (Pubitemid 34602069)
74. Knight A, Askling J, Granath F, Sparen P, et al. Urinary bladder cancer in Wegener's granulomatosis : risks and relation to cyclophosphamide. Ann Rheum Dis 2004 ; 63 : 1307-1311. (Pubitemid 39273514)
75. Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, et al. Malignancies in Wegener's granulomatosis : incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008 ; 35 : 100-105.
76. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996 ; 124 : 477-484.
77. Westman KW, Bygren PG, Olsson H, Ranstam J, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998 ; 9 : 842-852.
78. Stone JH, Holbrook JT, Marriott MA, Tibbs AK, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006 ; 54 : 1608-1618.
79. Klawansky S, Komaroff E, Cavanaugh PF Jr, Mitchell DY, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 2003 ; 14 : 570-576.
80. Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006 ; 17 : 3223-3232. (Pubitemid 44707784)
81. Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture : a growing concern. Kidney Int 2008 ; 74: 721-731.
82. Royal College of Physicians NOS, Bone and Tooth Society of Great Britain. Glucocorticoid induced osteoporosis - guidelines for the prevention and treatment. London : Royal College of Physicians, 2002.
83. Nawata H, Soen S, Takayanagi R, Tanaka I, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research(2004). J Bone Miner Metab 2005 ; 23 : 105-109.
84. Miller PD, Roux C, Boonen S, Barton IP, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method : a pooled analysis of nine clinical trials. J Bone Miner Res 2005 ; 20 : 2105-2115. (Pubitemid 41698774)
85. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, et al. Alendronate treatment in women with normal to severely impaired renal function : an analysis of the fracture intervention trial. J Bone Miner Res 2007 ; 22 : 503-508. (Pubitemid 47457426)
86. Grossman JM, Gordon R, Ranganath VK, Deal C, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res(Hoboken).
87. Shoben AB, Rudser KD, de Boer IH, Young B, et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008 ; 19 : 1613-1619.
88. Ishani A, Blackwell T, Jamal SA, Cummings SR, et al. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 2008 ; 19 : 1430-1438.
89. Morgan MD, Turnbull J, Selamet U, Kaur-Hayer M, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides : a matched-pair cohort study. Arthritis Rheum 2009 ; 60 : 3493-3500.
90. Muntner P, He J, Astor BC, Folsom AR, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease : results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005 ; 16 : 529-538. (Pubitemid 41725151)
91. Shlipak MG, Fried LF, Cushman M, Manolio TA, et al. Cardiovascular mortality risk in chronic kidney disease : comparison of traditional and novel risk factors. JAMA 2005 ; 293 : 1737-1745.
92. Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med 2007 ; 356 : 1438-1444. (Pubitemid 46562358)
93. Park MC, Park YB, Jung SY, Chung IH, et al. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004 ; 13 : 569-574. (Pubitemid 39145485)
94. Kosasa TS, McNamee PI, Morton C, Huang TT. Pregnancy rates after transfer of cryopreserved blastocysts cultured in a sequential media. Am J Obstet Gynecol 2005 ; 192 : 2035-2039 ; discussion 2039-2040.
95. Gosden RG. Prospects for oocyte banking and in vitro maturation. J Natl Cancer Inst Monogr 2005 : 60-63.
96. Clowse ME, Behera MA, Anders CK, Copland S, et al. Ovarian preservation by GnRH agonists during chemotherapy : a meta-analysis. J Womens Health (Larchmt) 2009 ; 18 : 311-319.
97. Aboulghar MA, Mansour RT, Serour GI, Fahmy I, et al. Fertilization and pregnancy rates after intracytoplasmic sperm injection using ejaculate semen and surgically retrieved sperm. Fertil Steril 1997 ; 68 : 108-111. (Pubitemid 27283725)
98. Ranganathan P, Mahran AM, Hallak J, Agarwal A. Sperm cryopreservation for men with nonmalignant, systemic diseases : a descriptive study. J Androl 2002 ; 23 : 71-75. (Pubitemid 34001131)
99. Vine MF, Margolin BH, Morrison HI, Hulka BS. Cigarette smoking and sperm density : a meta-analysis. Fertil Steril 1994 ; 61 : 35-43. (Pubitemid 24030676)
100. Hogan SL, Falk RJ, Chin H, Cai J, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005 ; 143 : 621-631.
101. Pagnoux C, Hogan SL, Chin H, Jennette JC, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis : comparison of two independent cohorts. Arthritis Rheum 2008 ; 58 : 2908-2918.
102. Han WK, Choi HK, Roth RM, McCluskey RT, et al. Serial ANCA titers : useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003 ; 63 : 1079-1085.
103. Jayne DR, Chapel H, Adu D, Misbah S, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000 ; 93 : 433-439. (Pubitemid 30459921)
104. Ito-Ihara T, Ono T, Nogaki F, Suyama K, et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract 2006 ; 102 : c35-42.
105. Muso E, Ito-Ihara T, Ono T, Imai E, et al. Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis 2004 ; 57 : S17-18.
106. Hasegawa M, Watanabe A, Takahashi H, Takahashi K, et al. Treatment with cytapheresis for antineutrophil cytoplasmic antibody-associated renal vasculitis and its effect on anti-inflammatory factors. Ther Apher Dial 2005 ; 9 : 297-302. (Pubitemid 41800797)
107. Hasegawa M, Ohashi A, Kabutan N, Hiramatsu S, et al. Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis : a pilot study of 21 patients. Ther Apher Dial 2006 ; 10 : 412-418. (Pubitemid 44652201)
108. Kojima K, Okada Y, Kushimoto H, Kawamura N, et al. Two cases of Goodpasture's syndrome - clinicopathological studies and relapse. Nippon Jinzo Gakkai Shi 1993 ; 35 : 89-96. (Pubitemid 23192539)
109. Levy JB, Lachmann RH, Pusey CD. Recurrent Goodpasture's disease. Am J Kidney Dis 1996 ; 27 : 573-578.
110. Fonck C, Loute G, Cosyns JP, Pirson Y. Recurrent fulminant anti-glomerular basement membrane nephritis at a 7-year interval. Am J Kidney Dis 1998 ; 32 : 323-327.
111. Khandelwal M, McCormick BB, Lajoie G, Sweet J, et al. Recurrence of anti-GBM disease 8 years after renal transplantation. Nephrol Dial Transplant 2004 ; 19 : 491-494. (Pubitemid 38196007)
112. Martinez V, Cohen P, Pagnoux C, Vinzio S, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies : results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008 ; 58 : 308-317.
113. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007 ; 18 : 2180-2188. (Pubitemid 47041083)
114. Giusti D, Hayton W Dosage regimen adjustment. Drug Intel Clin Pharm 1973 ; 7 : 382-387.
115. Jayne D, Rasmussen N, Andrassy K, Bacon P, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003 ; 349 : 36-44. (Pubitemid 36765101)
116. Koldingsnes W, Nossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 2003 ; 30 : 80-88. (Pubitemid 36077776)
117. Metzler C, Miehle N, Manger K, Iking-Konert C, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007 ; 46 : 1087-1091. (Pubitemid 47050609)
118. Hiemstra TF, Walsh M, Mahr A, Savage CO, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis : a randomized controlled trial. JAMA 2010 ; 304 : 2381-2388.
119. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch CoTrimoxazole Wegener Study Group. N Engl J Med 1996 ; 335 : 16-20.
120. Reinhold-Keller E, De Groot K, Rudert H, Nolle B, et al. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996 ; 89 : 15-23. (Pubitemid 26023960)
121. de Groot K, Rasmussen N, Bacon PA, Tervaert JW, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005 ; 52 : 2461-2469. (Pubitemid 41117433)
122. Lionaki S, Hogan SL, Jennette CE, Hu Y, et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int 2009 ; 76 : 644-651.
123. Bolton WK. Goodpasture's syndrome. Kidney Int 1996 ; 50 : 1753-1766. (Pubitemid 26364285)
124. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001 ; 134 : 1033-1042. (Pubitemid 32488657)
125. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996 ; 7 : 33-39. (Pubitemid 26067089)
126. Nowack R, Gobel U, Klooker P, Hergesell O, et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis : a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999 l; 10 : 1965-1971. (Pubitemid 29402518)
127. Booth A, Harper L, Hammad T, Bacon P, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004 ; 15 : 717-721. (Pubitemid 38294802)
128. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005 ; 52 : 262-268. (Pubitemid 40129256)
129. Jones RB, Tervaert JW, Hauser T, Luqmani R, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363 : 211-220.
130. Stone JH, Merkel PA, Spiera R, Seo P, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363 : 221-232.
131. Bajema IM, Hagen EC, Hansen BE, Hermans J, et al. The renal histopathology in systemic vasculitis : an international survey study of inter- and intra-observer agreement. Nephrol Dial Transplant 1996 ; 11 : 1989-1995. (Pubitemid 26345463)
132. Joh K, Muso E, Shigematsu H, Nose M, et al. Renal pathology of ANCA-related vasculitis : proposal for standardization of pathological diagnosis in Japan. Clin Exp Nephrol 2008 ; 12 : 277-291.
133. Berden AE, Ferrario F, Hagen EC, Jayne DR, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010 ; 21 : 1628-1636.